Mirabilis Medica
Medical device company focusing on the treatment of uterine fibroids
About Mirabilis Medica
Mirabilis Medical specializes in developing non-invasive therapeutic ultrasound systems, primarily targeting the ablation of uterine fibroids. Uterine fibroids are benign tumors that can cause significant symptoms such as heavy menstrual bleeding, pain, pregnancy loss, and infertility. The company's innovative technology utilizes high-resolution ultrasound imaging to allow physicians to precisely locate and treat fibroids without the need for invasive surgery. This approach offers a safer and less disruptive alternative to traditional surgical methods. Mirabilis Medical operates in the healthcare sector, focusing on women's health and serving patients who suffer from symptomatic uterine fibroids. The business model revolves around the development and commercialization of its proprietary ultrasound system, generating revenue through the sale and licensing of its technology. The company is currently in the investigational phase in the United States, as mandated by federal law.
Source: Dealroom company dataNews
Open roles
Mirabilis Medica in the Bothell ecosystem
The Mirabilis Medica office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Arboretum Ventures
GSR Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mirabilis Medica on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mirabilis Medica on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


